Eli Lilly and Company

LLY

939.47 (-1.51%) 14.15

Health Care

Pharmaceuticals

Eli Lilly and Company discovers develops manufactures and markets human pharmaceutical products in the United States Europe China Japan and internationally. The company offers cardiometabolic health products including Basaglar Humalog Humalog Mix 75/25 Humalog U-100 Humalog U-200 Humalog Mix 50/50 insulin lispro insulin lispro protamine insulin lispro mix 75/25 Humulin Humulin 70/30 Humulin N Humulin R Humulin U-500 for diabetes; Jardiance Mounjaro and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin’s lymphoma; and Verzenio for breast cancer. In addition the company offers immunology products which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis atopic dermatitis severe alopecia areata and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis psoriatic arthritis ankylosing spondylitis and non-radiographic axial spondylarthritis. Further it provides Emgality for migraine prevention and episodic cluster headache as well as Kisubla for symptomatic Alzheimer’s disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech Inc. for lebrikizumab as well as license agreements with Almirall S.A. for Ebglyss; and Chugai Pharmaceutical Co. Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis Indiana.

Quality Checklist 6/8

5Y Shares Out Change < 0%

ROIC > 10%

Current Ratio > 1

Net Margin > 10%

Past Net Income CAGR > 0%

Est. EPS Growth > 5%

Debt/Equity < 1

Quick Ratio > 1

0.0%of Portfolio

My holdings

Day change:

Total change:

Cost basis:

Market cap: $840.66(B)

EV: $826.55(B)

Total Equity: $26.54(B)

Earnings date: Apr-30-2026

P/E: 40.85

Forward P/E: 27.10

P/FCF: 93.67

P/S: 12.93

P/B: 31.69

EPS: $23.0

EPS (fwd): $34.7

FCF/share: $10.0

Revenue/share: $72.6

Book value/share: $29.6

ROIC: 32.9%

ROA: 19.3%

ROE: 96.8%

Debt/Equity: 1.65

Current Ratio: 1.60

Gross margin: 83.0%

Operating margin: 45.1%

Net margin: 31.7%

Dividend/share: $6.0

Div. yield: 0.64%

All Valuation Overview Growth Financials & KPIs Competitors & Peer Comparison Ownership Tools

LLY Valuation & Price Targets

Current Price

$939

Favorite Valuation Methods

PEvaluation

N/A

Analyst targets

N/A

DCF (2-stage)

N/A

More Valuation Methods

DCF (simple)

N/A

DCF (exit mult.)

N/A

DDM

N/A

EPS growth

N/A

Revenue growth

N/A

Peter Lynch FV

N/A

Graham No.

N/A

PEvaluation

2% overvalued

Low

$689

Mid

$919

High

$1148

Current price

$939

Fair P/E

Margin of safety

EPS

Market Model

Economic moat: Very wide

EPS Estimates

	Low	Avg	High	#
FY+1	33.5	34.7	38.0	28
FY+2	37.9	42.1	46.5	28
FY+3	43.6	49.0	57.0	21
FY+4	49.4	55.1	63.8	15
FY+5	52.7	60.8	71.2	15

Analyst Price Targets

34% undervalued

Low

$850

Mid

$1260

High

$1500

Current price

$939

Analyst Recommendations

Strong Buy6

Buy18

Hold6

Sell1

Strong Sell0

2-stage DCF

First Stage Duration: 5 Years

Starting Free Cash Flow
First Stage Growth Rate
LowMidHigh

Terminal Growth Rate
LowMidHigh

Discount Rate

Discounted Cash Flow

Forecast years: 5 Years

Terminal Growth Rate
LowMidHigh

Discount Rate

Free cash flow estimates:

Y+1 est.

Y+2 est.

0.00%

Y+3 est.

0.00%

Y+4 est.

0.00%

Y+5 est.

0.00%

Discounted Cash Flow (exit mult.)

Forecast years: 5 Years

Exit FCF Multiple
LowMidHigh

Discount Rate

Free cash flow estimates:

Y+1 est.

Y+2 est.

0.00%

Y+3 est.

0.00%

Y+4 est.

0.00%

Y+5 est.

0.00%

Dividend Discount Model

Annual Dividend
First Stage Length (Years): 0 Years

First Stage Growth Rate
Final Growth Rate
Discount Rate

EPS Growth

Forecast years: 5 Years

Starting EPS
EPS Growth Rate
LowMidHigh

Final P/E
LowMidHigh

Discount Rate

Revenue Growth Valuation

Forecast Years: 10 Years

Base Revenue
Revenue Growth Rate
LowMidHigh

Final Net Margin
LowMidHigh

Final P/E Ratio
LowMidHigh

Discount Rate

Peter Lynch Fair Value

Earnings Per Share
Growth Rate

Graham Formula

Earnings Per Share
EPS Growth (7-10 years)
Government Bond Rate

About

Terms & privacy

Price charts & news courtesy of TradingView

Blog

Contact